BioSpace News Archive

Latest data from the CIRLL study to be presented at ASCO 2021 remain encouraging, demonstrate good, continued enrollment, are consistent with previous results and are updated over data contained in abstract #7556 released today

New data from across Eli Lilly and Company’s oncology portfolio will be presented at the 2021 American Society of Clinical Oncology Annual Meeting, held June 4-8, 2021.

LYNPARZA is the first targeted medicine to show clinical benefit in the adjuvant setting for patients with germline BRCA-mutated high-risk HER2-negative early breast cancer CALQUENCE shows sustained four-year clinical benefit in 1st-line chronic lymphocytic leukemia and lower atrial fibrillation rates in previously treated patients vs. ibrutinib

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will present the latest research from its early stage clinical development programs in two presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting,

Data from 20 abstracts demonstrate value of company’s blood tests across the continuum of cancer care, including: screening, therapy selection, residual and recurrent disease detection, and biopharmaceutical drug development

Clovis Oncology Highlights Rubraca ® (rucaparib) and Lucitanib Data at 2021 ASCO Annual Meeting

Amgen (NASDAQ: AMGN) will present at the Cowen 2nd Annual Virtual Oncology Innovation Summit at 11:20 a.m. ET on Friday , May 21, 2021. David M. Reese , M.D., executive vice president of Research and Development at Amgen, will present at the conference.

Sofusa is a drug delivery platform technology which delivers biologic therapies through the skin directly into the lymphatic system with potential to improve efficacy and safety and reduce the required dosing (as compared to traditional systemic or subcutaneous injections or infusions).